 |
|
|
| |
Safety and Efficacy of Glecaprevir/Pibrentasvir in Adults With Chronic Hepati is C Virus Infection Genotype 1-6 as a Function of Chronic Kidney Disease Stage
|
| |
| |
AASLD: EXPEDITION-4: EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR (ABT-493/ABT-530) IN PATIENTS WITH RENAL IMPAIRMENT AND CHRONIC HEPATITIS C VIRUS GENOTYPE 1 - 6 INFECTION - (11/15/16)
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Stanislas Pol1, Paul Pockros2, David Pugatch3, Norbert Brau4, Charles Landis5, Ira Jacobson6, Magdy Elkhashab7, Joe Sasadeusz8, Albert Tran9,
Yiran Hu3, Matt hew Kosloski3, Federico J Mensa3
1Groupe Hospitalier Cochin-Saint Vincent De Paul, Paris, France; 2Division of Gastroenterology/Hepatology, Scripps Clinic, La Jolla, California, United States; 3AbbVie Inc., North Chicago, Illinois, United States;
4James J Peters VA Medical Center, Bronx, New York, United States; 5Division of Gastroenterology, University of Washington, Seattle, Washington, United States; 6Mount Sinai Beth Israel, New York, New York, United States ;
7Toronto Liver Centre, Toronto, Ontario, Canada; 8Royal Melbourne Hospital, Melbourne, Australia; 9University Hospital of Nice, Digestive Centre, Nice, F-06202, Cedex 3, France
|
| |
|
|
|
|
|
